ABSTRACT

Why anticoagulated patients are a priority in covid-19 vaccination: myths and realities

The COVID-19 pandemic has challenged healthcare systems worldwide, given the scarcity of effective treatments, vaccination has emerged as the primary strategy to mitigate this disease. This approach takes on additional importance in the context of patients with heart disease, who constitute a high-risk group for morbidity and mortality. In this regard, it is essential to understand the implications of drugs used in the treatment of these diseases, including anticoagulants, particularly in the face of the proliferation of misinformation and myths related to vaccines, their development, and possible adverse effects. With the aim of providing relevant guidance, this literature review aspired to equip healthcare professionals with necessary recommendations on the COVID-19 vaccine and the management of anticoagulant therapy, thereby facilitating effective and timely decision-making. Thus, evidence suggests that intramuscular vaccine administration in this group is considered safe, with minimal incidence of hematomas, supporting the recommendation to vaccinate these patients, in whom the general vaccination recommendation is even greater than in the general population. Finally, anticoagulated patients are urged to follow the instructions of health authorities regarding their indication and administration.

Key words: Anticoagulation; COVID-19; vaccination; SARS-CoV-2; direct anticoagulants; Warfarin; DOAC.